CoChat

Optimization of transfection methods for human lymphoblast TK6 cell line

Open access
Ewunkem, Akamu Jude, Agee, Kyle · 2023 · Gene & Protein in Disease

The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index; none of the 62 sources its claims cite is checked for support yet.

Abstract

Transfection has recently gained attention in the field of biomedical research due to its ability to manipulate gene expression. Every mammalian cell type has a characteristic set of requirements for optimal transfection. Some cells can be difficult to transfect and require optimization for successful transfection. Human lymphoblast TK6 cell line, an important cell line for genotoxic studies, is known to be extremely hard to transfect. Thus, optimizing transfection methods for human lymphoblast TK6 are increasingly important. To accomplish this, TK6 human lymphoblasts were transfected with plasmid constructs that expressed green fluorescent protein (GFP) and NanoLuc® activity. We compared the transfection efficiency of three commercially available transfection reagents, including Amaxa 96-well Nucleofection procedure using various solutions (SF, SE, and SG), Lipofectamine LTX, and Metafectene Pro®. The transfection efficiency and toxicity of various reagents were tested by fluorescence microscopy, luciferase activity, and cell viability assays. Amaxa 96-well Nucleofection Solution SF was identified as the best transfection reagent due to its relatively high luciferase activity, acceptable cell viability (80%), and GFP transfection efficiency (80%). Optimal conditions for transfection utilized with this reagent included 0.4 μg of plasmid DNA, 1.8 × 105 cells, and using the DS 137 Nucleofector program.

Overview

CoChat Summary

TL;DR

This study compared Metafectene Pro, Lipofectamine LTX, and Amaxa 96-well Nucleofection for transfecting hard-to-transfect human TK6 lymphoblasts. Amaxa Nucleofection with Solution SF and program DS 137 was identified as optimal, yielding high GFP transfection efficiency, acceptable viability, and the strongest luciferase signal among the tested reagents.

Key findings

  • Amaxa 96-well Nucleofection Solution SF with program DS 137 was best: the abstract reports optimized conditions of 0.4 µg plasmid DNA, 1.8 × 10^5 cells, 80% viability, and 80% GFP transfection efficiency; results report ~80% GFP efficiency and ~85% viability for 0.4 µg, with luciferase RLU ~5.4 × 10^5 (discussion reports RLU = 5.1 × 10^5 and toxicity ~15%). Amaxa yielded the strongest luciferase signal of the three reagents after 24 and 36 h.
  • Metafectene Pro gave ~96% cell viability regardless of ratio, with maximal transfection efficiency at reagent:DNA ratio 3 using 1.0 µg DNA at 24 and 36 h, but no nanoluciferase activity was detected under optimal conditions, so it could not be used in this system.
  • Lipofectamine LTX achieved at least 80% transfection efficiency with no significant toxicity at 24 and 36 h; luciferase activity was significantly greater than control, with a 30% increase at 36 h versus 24 h, and nanoluciferase expression around 1.8 × 10^5 RLU.
  • In secondary Amaxa optimization, 0.4 µg DNA gave significantly greater viability than 0.5 µg at 24 and 36 h, with no significant difference in GFP efficiency between 0.4 and 0.5 µg; 0.4 µg pNL1.1CMV produced significantly greater luciferase activity than 0.5 µg, with maximal expression at 36 h.

Methods

  • TK6 human p53-proficient B-lymphoblastic cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine and 10% FBS at 37°C/5% CO2; cells were passaged at 2.0 × 10^5 cells/ml, media changed every 36 h, and passaged 12–14 h before experiments.
  • Plasmids used were pGFPmax (GFP), pNL1.1.CMV (nanoluciferase), and pNL1.2[Nluc] promoter-less control. Transfections used Metafectene Pro (ratios 1:2–1:6; 0.5/1.0 µg DNA), Lipofectamine LTX (0.5–1.0 µg DNA; PLUS 1.5–2.5 µl; lipofectamine 3.75–10.0 µl), and Amaxa 96-well Nucleofection (initial SE/SF/SG with 0.4 µg pmaxGFP; secondary SF with DS 137 and 0.4/0.5 µg pGFPmax or pNL1.1CMV).
  • Assays at 24 and 36 h included GFP fluorescence microscopy for transfection efficiency (GFP+ cells divided by total cells by brightfield), Nano-Glo luciferase assay, and Vi-cell viability. Transfection experiments were conducted in duplicates and repeated twice; luciferase assays are reported as triplicates/duplicates.

Limitations

  • The paper has no dedicated limitations section. Stated caveats include: Amaxa nucleofection was more toxic than the other methods due to long-lasting pulses or polarization from the electric field and gave overall weak but acceptable viability; Metafectene Pro produced no detectable nanoluciferase activity, possibly due to inhibition/interference with NanoLuc; and no single delivery method or reagent works for all cells, with cytotoxicity and efficiency varying by reagent, protocol, and cell type.
  • Evident from the text: only one cell line (TK6) was tested; experiments were in duplicates and repeated twice; statistical tests are not named; some optimization/viability data are “not shown”; and reported values vary between abstract, results, and discussion (e.g., viability 80% vs ~85%; RLU ~5.4 × 10^5 vs 5.1 × 10^5).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.36922/gpd.0353

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY · From the PDF
Image 2
CC-BY · From the PDF
Figure 3
Figure 3 CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 19 Not checked · 52 Own results and interpretations

35 more claims

Create a free account to see all 71 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 15
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Research works printed but not linked: 4

  1. Karra D, Dahm R. Transfection techniques for neuronal cells. Journal of Neuroscience. 2010 May 5;30(18):6171-7.
  2. Park JS, Surendran S, Kamendulis LM, Morral N. Comparative nucleic acid transfection e cacy in primary hepatocytes for gene silencing and functional studies. BMC research notes. 2011 Dec;4(1):1- 8.
  3. Parson II CD. A Generalizable Method to Normalize Luciferase Activity in Transiently Transfected B cells (Doctoral dissertation, North Carolina Agricultural and Technical State University).
  4. Badakov R, Jaźwińska A. E cient transfection of primary zebra sh broblasts by nucleofection. Cytotechnology. 2006 Jun 1;51(2):105-10.

Cited by

See all 3

Metadata

Authors
Ewunkem, A. J., & Agee, K.
Affiliations
Winston-Salem State University (US)
Venue
Gene & Protein in Disease
Published
2023-05-29
Volume
2
Issue
2
Pages
0353
ISSN
2811-003X (ISSN-L)
OpenAlex
W4382073817
Cited by
3
References
73
Citations by year
2025: 1 · 2024: 2
FWCI
0.20
Type
journal article
Language
en
Open access
Locations
  • Gene & Protein in Disease (publishedVersion, cc-by)
  • Research Square (submittedVersion, cc-by)
Funders
National Institute of General Medical Sciences (S06GM076530)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
Keywords
transfection optimization, transfection reagents, nucleofection, transfection efficiency, cell viability, genotoxicity testing, plasmid DNA delivery, GFP expression, NanoLuc luciferase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.